- Pertuzumab as first-line treatment of patients with metastatic HER2-positive breast cancer2012 | Publication without faculty affiliation
- Pertuzumab in breast cancer2016 | Publication without faculty affiliation
- New agent to enhance targeted therapy of metastatic HER2+ breast cancer - pertuzumab2013 | First Faculty of Medicine
- Pertuzumab in the neoadjuvant treatment of breast cancer2021 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: BO28407Publication without faculty affiliation
- Fixní kombinace pertuzumabu a trastuzumabu v subkutánní injekci2021 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BO28407Publication without faculty affiliation
- Lékový profil: Pertuzumab2013 | Third Faculty of Medicine
- Experience in the treatment of advanced HER2 positive breast tumor in University Hospital in Motol2016 | Publication without faculty affiliation
- Research Report University Hospital clinical trial BO28407Publication without faculty affiliation
- News in anti-HER2 targeted therapy in breast cancer +12013 | First Faculty of Medicine
- Ovlivní Phesgo (kombinace pertuzumabu a trastuzumabu) péči o pacientky s HER2 pozitivním karcinomem prsu?2021 | Third Faculty of Medicine
- The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States2023 | Faculty of Social Sciences
- Využití pertuzumabu v léčbě metastatického karcinomu prsu2021 | First Faculty of Medicine
- Targeted therapy in HER2-positive breast cancer2013 | Faculty of Medicine in Hradec Králové
- Clinical importance of her-3 in breast cancer2020 | First Faculty of Medicine, Third Faculty of Medicine
- Overview of biological therapy for HER2-positive metastatic breast cancer2015 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Neoadjuvant systemic therapy of breast cancer2018 | First Faculty of Medicine
- Terapie časného HER2 pozitivního karcinomu prsu2022 | Publication without faculty affiliation
- New treatment options for HER2-dependent metastatic breast cancer2011 | First Faculty of Medicine
- What should a general practicioner know about the most common cancers - Breast cancer2018 | Faculty of Medicine in Pilsen
- Adjuvantní a neoadjuvantní léčba časného HER pozitivního karcinomu prsu. Specifika léčby HER2 pozitivního / HR pozitivního karcinomu prsu2022 | Publication without faculty affiliation
- Using 'Costs States' in a Semi-Markov Model to Estimate Cost-Effectiveness with an Illustration for Metastatic HER2 Breast Cancer in the Czech RepublicPublication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no.MO22324Publication without faculty affiliation
- Using 'Costs States' in a Semi-Markov Model to Estimate Cost-Effectiveness: an Illustration for Metastatic HER2 Breast Cancer in the Czech Republic2020 | Faculty of Social Sciences
- Advances in targeted therapy for breast cancer2011 | First Faculty of Medicine
- Vinorelbine, a second-generation Vinca alkaloid - its place in the treatment of advanced and metastatic breast cancer2014 | First Faculty of Medicine
- Nová sféra neoadjuvantní léčby HER2-pozitivního karcinomu prsu2016 | First Faculty of Medicine
- Neviditelné ženy nejsou vidět a ani slyšet2017 | First Faculty of Medicine